PMID- 16280073
OWN - NLM
STAT- MEDLINE
DCOM- 20060717
LR  - 20181113
IS  - 1477-7827 (Electronic)
IS  - 1477-7827 (Linking)
VI  - 3
DP  - 2005 Nov 9
TI  - Subcutaneously administered Menopur, a new highly purified human menopausal 
      gonadotropin, causes significantly fewer injection site reactions than Repronex 
      in subjects undergoing in vitro fertilization.
PG  - 62
AB  - BACKGROUND: The safety and tolerability of a new highly purified, urine-derived 
      human menopausal gonadotropin (hMG) preparation [Menopur] was compared with a 
      currently available hMG [Repronex] in women undergoing in vitro fertilization 
      (IVF). METHODS: This was a randomized, open-label, parallel-group, multicenter 
      study conducted in subjects undergoing IVF. Women (N = 125), 18-39 years of age, 
      underwent pituitary down-regulation with leuprolide acetate beginning 7 days 
      prior to onset of menses and continuing up to the day before hCG administration. 
      Subjects were randomized to receive subcutaneous (SC) Menopur (n = 61) or 
      Repronex SC (n = 64) for a maximum of 12 days. All adverse events (AEs) were 
      recorded and subject self-assessments of injection site reactions were recorded 
      in a daily diary. RESULTS: Significantly fewer subjects in the Menopur group 
      reported injection site reactions (P < 0.001) compared to the Repronex group. 
      Overall, there was no statistically significant difference in the incidence of 
      AEs between the two treatment groups. CONCLUSION: Menopur SC offers a greater 
      safety and tolerability profile compared to Repronex SC.
FAU - Keye, William R
AU  - Keye WR
AD  - William Beaumont Hospital, In Vitro Fertility Clinic, Royal Oak, Michigan, USA. 
      wkeye@beaumont.edu
FAU - Webster, Bobby
AU  - Webster B
FAU - Dickey, Richard
AU  - Dickey R
FAU - Somkuti, Stephen
AU  - Somkuti S
FAU - Crain, Jack
AU  - Crain J
FAU - Scobey, M Joseph
AU  - Scobey MJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20051109
PL  - England
TA  - Reprod Biol Endocrinol
JT  - Reproductive biology and endocrinology : RB&E
JID - 101153627
RN  - 0 (Organic Chemicals)
RN  - 0 (Repronex)
RN  - 61489-71-2 (Menotropins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Humans
MH  - Injections, Subcutaneous/*adverse effects
MH  - Menotropins/*administration & dosage/adverse effects
MH  - Organic Chemicals/administration & dosage/adverse effects
MH  - Pain/etiology
PMC - PMC1309620
EDAT- 2005/11/11 09:00
MHDA- 2006/07/18 09:00
PMCR- 2005/11/09
CRDT- 2005/11/11 09:00
PHST- 2005/06/27 00:00 [received]
PHST- 2005/11/09 00:00 [accepted]
PHST- 2005/11/11 09:00 [pubmed]
PHST- 2006/07/18 09:00 [medline]
PHST- 2005/11/11 09:00 [entrez]
PHST- 2005/11/09 00:00 [pmc-release]
AID - 1477-7827-3-62 [pii]
AID - 10.1186/1477-7827-3-62 [doi]
PST - epublish
SO  - Reprod Biol Endocrinol. 2005 Nov 9;3:62. doi: 10.1186/1477-7827-3-62.